Relationship between cytokine profiles and clinical outcomes in patients with systemic sclerosis

Autoimmunity Reviews

Volumn 10, Issue 2, 2010, Pages 65-73

  Baraut, Julie ^a   Michel, Laurence ^a   Verrecchia, Franck ^b   Farge, Dominique ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITÉ DE NANTES   (France)

Author keywords

Cytokines; Fibrosis; Systemic sclerosis; T lymphocytes

Indexed keywords

ANTIFIBROTIC AGENT; AUTOANTIBODY; BOSENTAN; CONNECTIVE TISSUE GROWTH FACTOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOKINE; DASATINIB; IMATINIB; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 16; INTERLEUKIN 1ALPHA; INTERLEUKIN 4; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MEDI 546; MEDI 551; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTEIN TYROSINE KINASE INHIBITOR; QAX 576; RAPAMYCIN; RITUXIMAB; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBODY PRODUCTION; B LYMPHOCYTE; BLOOD LEVEL; CD4+ T LYMPHOCYTE; COLLAGEN SYNTHESIS; CONNECTIVE TISSUE; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE COURSE; DISEASE SEVERITY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; FIBROSIS; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INTERSTITIAL LUNG DISEASE; LUNG FIBROSIS; LUNG LAVAGE; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHOTOTHERAPY; REGULATORY T LYMPHOCYTE; REVIEW; SCLERODERMA; SKIN BIOPSY; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH2 CELL; TREATMENT OUTCOME; ULTRAVIOLET A RADIATION; ULTRAVIOLET IRRADIATION;

EID: 78650415467     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2010.08.003     Document Type: Review

References (58)

1. Czömpöly T., Simon D., Czirják L., Németh P. Anti-topoisomerase I autoantibodies in systemic sclerosis. Autoimmun Rev 2009, 8:692-696.
2. Cavazzana I., Angela C., Paolo A., Stefania Z., Angela T., Franco F. Anti-RNA polymerase III antibodies: a marker of systemic sclerosis with rapid onset and skin thickening progression. Autoimmun Rev 2009, 8:580-584.
3. Steen V.D., Medsger T.A. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000, 43:2437-2444.
4. Ranque B., Mouthon L. Geoepidemiology of systemic sclerosis. Autoimmun Rev 2010, 9:311-318.
5. Akimoto S., Abe M., Ishikawa O., Takagi H., Mori M. HLA-DRB1 and DQB1 genes in anticentromere antibody positive patients with SSc and primary biliary cirrhosis. Ann Rheum Dis 2001, 60:639-640.
6. Agarwal S.K., Tan F.K., Arnett F.C. Genetics and genomic studies in scleroderma (systemic sclerosis). Rheum Dis Clin North Am 2008, 34:17-40.
7. Milano A., Pendergrass S.A., Sargent J.L., George L.K., McCalmont T.H., Connolly M.K., et al. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS ONE 2008, 3:e2696.
8. Mora G.F. Systemic sclerosis: environmental factors. J Rheumatol 2009, 36:2383-2396.
9. Randone S.B., Guiducci S., Cerinic M.M. Systemic sclerosis and infections. Autoimmun Rev 2008, 8:36-40.
10. Gabrielli A., Avvedimento E.V., Krieg T. Scleroderma 2009, 360:1989-2003.
11. Abraham D.J., Varga J. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 2005, 26:587-595.
12. Verrecchia F., Mauviel A. Transforming growth factor-beta and fibrosis. World J Gastroenterol 2007, 13:3056-3062.
13. O'Garra A., Steinman L., Gijbels K. CD4+ T-cell subsets in autoimmunity. Curr Opin Immunol 1997, 9:872-883.
14. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
15. Luger T.A., Bhardwaj R.S., Grabbe S., Schwarz T. Regulation of the immune response by epidermal cytokines and neurohormones. J Dermatol Sci 1996, 13:5-10.
16. Yokota K., Miyazaki T., Hirano M., Akiyama Y., Mimura T. Simvastatin inhibits production of interleukin 6 (IL-6) and IL-8 and cell proliferation induced by tumor necrosis factor-alpha in fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Rheumatol 2006, 33:463-471.
17. Borish L.C., Nelson H.S., Corren J., Bensch G., Busse W.W., Whitmore J.B., et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001, 107:963-970.
18. Granel B., Chevillard C., Dessein A. Interleukin 13 and interleukin 13 receptor involvement in systemic sclerosis. Rev Méd Interne 2007, 28:613-622.
19. Jiang H., Chess L. Regulation of immune responses by T cells. N Engl J Med 2006, 354:1166-1176.
20. Fossiez F., Djossou O., Chomarat P., Flores-Romo L., Ait-Yahia S., Maat C., et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996, 183:2593-2603.
21. Kurasawa K., Hirose K., Sano H., Endo H., Shinkai H., Nawata Y., et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 2000, 43:2455-2463.
22. Wurster A.L., Rodgers V.L., Satoskar A.R., Whitters M.J., Young D.A., Collins M., et al. Interleukin 21 Is a T Helper (Th) Cell 2 cytokine that specifically inhibits the differentiation of naive Th cells into interferon {gamma}-producing Th1 cells. J Exp Med 2002, 196:969-977.
23. Agarwal S.K., Gourh P., Shete S., Paz G., Divecha D., Reveille J.D., et al. Association of interleukin 23 receptor polymorphisms with anti-topoisomerase-I positivity and pulmonary hypertension in systemic sclerosis. J Rheumatol 2009, 36:2715-2723.
24. Radstake T.R., van Bon L., Broen J., Hussiani A., Hesselstrand R., Wuttge D.M., et al. The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFβ and IFNγ distinguishes SSc phenotypes. PLoS ONE 2009, 4:e5903.
25. Wing K., Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 2010, 11:7-13.
26. Kretschmer K., Apostolou I., Hawiger D., Khazaie K., Nussenzweig M.C., von Boehmer H. Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol 2005, 12:1219-1227.
27. Voo K.S., Wang Y., Santori F.R., Boggiano C., Wang Y., Arima K., et al. Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc Natl Acad Sci 2009, 106:4793-4798.
28. Ayyoub M., Deknuydt F., Raimbaud I., Dousset C., Leveque L., Bioley G., et al. Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express the TH17 lineage-specific transcription factor ROR t. Proc Natl Acad Sci 2009, 106:8635-8640.
29. Beriou G., Costantino C.M., Ashley C.W., Yang L., Kuchroo V.K., Baecher-Allan C., et al. IL-17-producing human peripheral regulatory T cells retain suppressive function. Blood 2009, 113:4240-4249.
30. Pohlers D., Brenmoehl J., Löffler I., Müller C.K., Leipner C., Schultze-Mosgau S., et al. TGF-[beta] and fibrosis in different organs - molecular pathway imprints, Biochimica et Biophysica Acta (BBA). Mol Basis Dis 2009, 1792:746-756.
31. Verrecchia F., Chu M., Mauviel A. Identification of novel TGF-β/Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J Biol Chem 2001, 276:17058-17062.
32. Verrecchia F., Laboureau J., Verola O., Roos N., Porcher R., Bruneval P., et al. Skin involvement in scleroderma-where histological and clinical scores meet. Rheumatol (Oxf) 2007, 46:833-841.
33. Lemoine S., Morva A., Youinou P., Jamin C. Regulatory B Cells in Autoimmune Diseases. Ann NY Acad Sci 2009, 1173:260-267.
34. Gu Y.S., Kong J., Cheema G.S., Keen C.L., Wick G., Gershwin M.E. The immunobiology of systemic sclerosiS. Semin Arthritis Rheum 2008, 38:132-160.
35. Baraut J, Farge D, Jean-Louis F, Kesmandt H, Durant C, Verrecchia F, et al, [Cytokines in systemic sclerosis.]. Pathol Biol (Paris) in press. http://doi:10.1016/j.patbio.2009.11.003.
36. Hasegawa M., Fujimoto M., Kikuchi K., Takehara K. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 1997, 24:328-332.
37. Hasegawa M., Sato S., Takehara K. Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1alpha (MIP-1alpha) and MIP-1beta) in patients with systemic sclerosis: MCP-1 and MIP-1alpha may be involved in the development of pulmonary fibrosis. Clin Exp Immunol 1999, 117:159-165.
38. Carulli M.T., Handler C., Coghlan J.G., Black C.M., Denton C.P. Can CCL2 serum levels be used in risk stratification or to monitor treatment response in systemic sclerosis?. Ann Rheum Dis 2008, 67:105-109.
39. Gourh P., Arnett F.C., Assassi S., Tan F.K., Huang M., Diekman L., et al. Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther 2009, 11:R147.
40. Matsushita T., Hasegawa M., Hamaguchi Y., Takehara K., Sato S. Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis. J Rheumatol 2006, 33:275-284.
41. Sato S., Hanakawa H., Hasegawa M., Nagaoka T., Hamaguchi Y., Nishijima C., et al. Levels of interleukin 12, a cytokine of type 1 helper T cells, are elevated in sera from patients with systemic sclerosis. J Rheumatol 2000, 27:2838-2842.
42. Matsushita T., Fujimoto M., Hasegawa M., Tanaka C., Kumada S., Ogawa F., et al. Elevated serum APRIL levels in patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF. J Rheumatol 2007, 34:2056-2062.
43. Bielecki M., Kowal K., Lapinska A., Chwiecko J., Skowronski J., Sierakowski S., et al. Diminished production of TWEAK by the peripheral blood mononuclear cells is associated with vascular involvement in patients with systemic sclerosis. Folia Histochem Cytobiol 2009, 47:465-469.
44. Yanaba K., Yoshizaki A., Muroi E., Hara T., Ogawa F., Usui A., et al. Elevated circulating TWEAK levels in systemic sclerosis: association with lower frequency of pulmonary fibrosis. J Rheumatol 2009, 36:1657-1662.
45. Yanaba K., Muroi E., Yoshizaki A., Hara T., Ogawa F., Shimizu K., et al. Serum CXCL16 concentrations correlate with the extent of skin sclerosis in patients with systemic sclerosis. J Rheumatol 2009, 36:1917-1923.
46. Furuse S., Fujii H., Kaburagi Y., Fujimoto M., Hasegawa M., Takehara K., et al. Serum concentrations of the CXC chemokines interleukin 8 and growth-regulated oncogene-alpha are elevated in patients with systemic sclerosis. J Rheumatol 2003, 30:1524-1528.
47. Yanaba K., Yoshizaki A., Muroi E., Hara T., Ogawa F., Shimizu K., et al. CCL13 is a promising diagnostic marker for systemic sclerosis. Br J Dermatol 2010, 162:332-336.
48. Scala E., Pallotta S., Frezzolini A., Abeni D., Barbieri C., Sampogna F., et al. Cytokine and chemokine levels in systemic sclerosis: relationship with cutaneous and internal organ involvement. Clin Exp Immunol 2004, 138:540-546.
49. Kim H., Park M., Kim H., Park S. Capillary dimension measured by computer-based digitalized image correlated with plasma endothelin-1 levels in patients with systemic sclerosis. Clin Rheumatol 2010, 29:247-254.
50. Duan H., Fleming J., Pritchard D.K., Amon L.M., Xue J., Arnett H.A., et al. Combined analysis of monocyte and lymphocyte messenger RNA expression with serum protein profiles in patients with scleroderma. Arthritis Rheum 2008, 58:1465-1474.
51. Distler J.H.W., Jüngel A., Kowal-Bielecka O., Michel B.A., Gay R.E., Sprott H., et al. Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. Arthritis Rheum 2005, 52:856-864.
52. Manetti M., Ibba-Manneschi L., Liakouli V., Guiducci S., Milia A.F., Benelli G., et al. The IL-1-like cytokine IL-33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis. Ann Rheum Dis 2009, 69:598-605.
53. Wipff J., Avouac J., Le Charpentier M., Varret M., Houtteman A., Ruiz B., et al. Dermal tissue and cellular expression of fibrillin-1 in diffuse cutaneous systemic sclerosis. Rheumatol (Oxf) 2010, 49:657-661.
54. Tashkin D.P., Elashoff R., Clements P.J., Goldin J., Roth M.D., Furst D.E., et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006, 354:2655-2666.
55. Poulalhon N., Farge D., Roos N., Tacheau C., Neuzillet C., Michel L., et al. Modulation of collagen and MMP-1 gene expression in fibroblasts by the immunosuppressive drug rapamycin. A direct role as an antifibrotic agent?. J Biol Chem 2006, 281:33045-33052.
56. Denton C.P., Merkel P.A., Furst D.E., Khanna D., Emery P., Hsu V.M., et al. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007, 56:323-333.
57. Kitamura Y., Namikawa H., Hayashi S., Yoshida T., Suzuki T., Hamasaki Y., et al. Effects of UVA irradiation following treatment with 8-methoxypsoralen on type I and type III collagen synthesis in normal and scleroderma fibroblast cultures. Arch Dermatol Res 2009, 301:507-513.
58. Gottenberg J., Guillevin L., Lambotte O., Combe B., Allanore Y., Cantagrel A., et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005, 64:913-920.